Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
about
Adoptive T cell therapy for cancer in the clinicGene Therapy for Pediatric Cancer: State of the Art and Future PerspectivesSub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancerChimeric antigen receptor therapy for cancerFlanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences.Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant.CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas.Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disordersThe immunology of Epstein-Barr virus infectionReactivation of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation.The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.The role of neutralizing antibodies for mouse mammary tumor virus transmission and mammary cancer development.Persistent gamma-herpesvirus infections: what can we learn from an experimental mouse model?Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.Contributions of gene marking to cell and gene therapies.Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease.T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.Autologous tumor rejection in humans: trimming the myths.Potential selection of LMP1 variants in nasopharyngeal carcinoma.Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity.New frontiers in cell-based immunotherapy of cancer.Dendritic cells and immunity against cancer.Recent developments in the prevention and treatment of Epstein-Barr virus-associated lymphoproliferative diseases.Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.Current status of chimeric antigen receptor therapy for haematological malignancies.Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning.Generation of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer.Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy.A sealed and unbreached system for purification, stimulation, and expansion of cytomegalovirus-specific human CD4 and CD8 T lymphocytes.A registry of HLA-typed donors for production of virus-specific CD4 and CD8 T lymphocytes for adoptive reconstitution of immune-compromised patients.Virus-Specific T Cells for the Immunocompromised Patient.Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.Detection of Epstein-Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow or peripheral blood stem cell transplantation.Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4+ T cells.
P2860
Q24680405-32C542E4-7E23-4B48-B302-8C0379FE5F8CQ24792778-5383D7C7-12A4-47E3-8DD9-0968B6BFA597Q24793123-ABDEEE07-3078-456D-B932-F7DDE956C4ABQ27013599-8F3E22D3-0C89-4706-820E-D3DF3F588F39Q33372388-0DEF9F4B-C30B-4D88-BDA6-F21F4857EC76Q33762569-98E89A4C-F9E8-4CD3-A02C-B3B3C2786BF9Q33851257-DEE0C5DF-6FB4-44EF-ABF5-560EC0575384Q33929813-2B4CF6E0-4374-49D2-8F38-44E65D9BF82DQ33971192-1DAB04EE-D969-4C7C-86B0-A13E5EB3037DQ34225567-0505C7B4-22AC-465B-873D-32955D998911Q34244404-8FBBC64B-C088-4AA9-A00F-5266A185A4EEQ34244446-53049072-47B9-4950-8D2C-FE4FBCD605CCQ34467281-57BEBABA-1909-489B-863F-C15A722A9AF0Q34584067-5EBADC22-4A67-4156-B5B4-A86971794879Q34622755-66EDB84B-9A32-41BC-9E49-DEDBA7FAFE23Q35059829-EC8A31D9-5AD7-4423-BF2F-22AF8D8CD987Q35787184-D6E1BD84-F953-48FA-A869-9EF34E6CD271Q36087036-F2028CE7-15B6-4AB0-809B-AB96EC13CF35Q36228567-2CCA1684-3CC2-40D5-B4BE-2B3B90DC1F23Q36389306-2B0727CF-54FA-4931-BAA9-925860C0E92AQ36569014-C0E81A20-5537-4FA3-BB53-84E245348E2FQ36944141-653DF90A-37F4-42D6-9F56-85D0D5B3EC79Q37190431-55BA0BE4-3068-4E67-8811-DAE7E1B4081CQ37481361-06E5EE70-0BC3-49AF-AC17-6474E18680E4Q37821074-938A3798-E9A3-4BE4-835B-DB13475D9187Q37906623-24AA0416-C04A-4D0D-83B8-4C782764EE6AQ38088635-365ED360-8A9A-483D-B3C4-4C139BC35F0FQ38631108-AD65111A-B58C-4125-96EA-1CB4E8F9CB3EQ38877813-5714C229-7BAC-4FDA-9F91-F9C5B234831EQ38923514-D71D30D7-23E0-4790-AB07-ED7CB975A6C4Q39013616-B88DE22A-B9F6-43D3-96B8-A4003CFE9AD8Q39111239-DC57B847-2BFA-4E00-9E7A-23C5571CE746Q39607047-3EC74206-B104-4A29-8D13-0B017C38A86BQ39752604-D6260AE8-89B0-4A38-BF0C-B4484BF104D5Q40193878-87D88C51-C8DE-4C34-8E04-65B747B1DAB1Q42205114-AF3A09FD-084C-4EE5-A6D7-3D667EF85CF0Q42654381-83CA84ED-BFD7-42A0-B844-0477636EEE5FQ42723067-2941E98F-9646-414D-A13D-E11DB40E0E91Q42725715-DEB8BA54-8292-49FB-93F1-37401D8AB18FQ43507906-19426B0C-6F86-4DD1-849E-5AF8AB0DFF50
P2860
Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
@en
type
label
Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
@en
prefLabel
Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
@en
P2860
P1476
Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
@en
P2093
P2860
P304
P356
10.1111/J.1600-065X.1997.TB00984.X
P577
1997-06-01T00:00:00Z